{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:35:24Z","timestamp":1781912124423,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":106,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.amjcard.2012.12.038","type":"journal-article","created":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T12:34:42Z","timestamp":1359462882000},"page":"1131-1138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Changes in Cardiovascular Risk Associated With Phentermine and Topiramate Extended-Release in Participants With Comorbidities and a Body Mass Index \u226527 kg\/m2"],"prefix":"10.1016","volume":"111","clinical-trial-number":[{"clinical-trial-number":"nct00553787","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michael H.","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Tonstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Oparil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schwiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley W.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2012.12.038_bib1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity"},{"key":"10.1016\/j.amjcard.2012.12.038_bib2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2012.12.038_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.amjcard.2012.12.038_bib4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMp1211277","article-title":"The FDA's assessment of two drugs for chronic weight management","volume":"367","author":"Colman","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2012.12.038_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3810\/pgm.2011.01.2243","article-title":"The pharmacological treatment and management of obesity","volume":"123","author":"Hussain","year":"2011","journal-title":"Postgrad Med"},{"key":"10.1016\/j.amjcard.2012.12.038_bib6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrd2037","article-title":"Anti-obesity therapies","volume":"5","author":"Melnikova","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.amjcard.2012.12.038_bib7","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1586\/erc.10.125","article-title":"Phentermine, topiramate and their combination for the treatment of adiposopathy (\u2018sick fat\u2019) and metabolic disease","volume":"8","author":"Bays","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.amjcard.2012.12.038_bib8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A\u00a06-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity","volume":"11","author":"Bray","year":"2003","journal-title":"Obes Res"},{"key":"10.1016\/j.amjcard.2012.12.038_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.amjcard.2005.03.053","article-title":"Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension","volume":"96","author":"Tonstad","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2012.12.038_bib10","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","article-title":"A\u00a0randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects","volume":"28","author":"Wilding","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.amjcard.2012.12.038_bib11","unstructured":"National Cholesterol Education Program. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Available at: http:\/\/www.nhlbi.nih.gov\/guidelines\/cholesterol\/atp3full.pdf. Accessed December 7, 2012."},{"key":"10.1016\/j.amjcard.2012.12.038_bib12","series-title":"The LEARN Program for Weight Management","author":"Brownell","year":"2000"},{"key":"10.1016\/j.amjcard.2012.12.038_bib13","unstructured":"Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Available at: http:\/\/ww.nhlbi.nih.gov\/guidelines\/hypertension\/. Accessed December 7, 2012."},{"key":"10.1016\/j.amjcard.2012.12.038_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1467-789X.2004.00127.x","article-title":"Effects of weight loss in overweight\/obese individuals and long-term lipid outcomes\u2014a systematic review","volume":"5","author":"Poobalan","year":"2004","journal-title":"Obes Rev"},{"key":"10.1016\/j.amjcard.2012.12.038_bib15","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/archinte.1987.00370100063012","article-title":"Long-term effects of modest weight loss in type II diabetic patients","volume":"147","author":"Wing","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2012.12.038_bib16","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2012.12.038_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/j.1550-8528.1999.tb00699.x","article-title":"Two-year changes in lipids\u00a0and lipoproteins associated with the maintenance of a 5% to 10%\u00a0reduction in initial weight: some findings and some questions","volume":"7","author":"Wadden","year":"1999","journal-title":"Obes Res"},{"key":"10.1016\/j.amjcard.2012.12.038_bib18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11695-011-0534-7","article-title":"Evolution of lipid profiles after bariatric surgery","volume":"22","author":"Garcia-Marirrodriga","year":"2012","journal-title":"Obes Surg"},{"key":"10.1016\/j.amjcard.2012.12.038_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.atherosclerosis.2011.02.012","article-title":"Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin\/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study","volume":"217","author":"Noguchi","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2012.12.038_bib20","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2010.650","article-title":"US trends in prevalence, awareness, treatment, and control of hypertension 1988\u20132008","volume":"303","author":"Egan","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2012.12.038_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1161\/CIRCULATIONAHA.105.542290","article-title":"Antihypertensive medication use among US adults with hypertension","volume":"113","author":"Gu","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.12.038_bib22","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00002018-200326140-00004","article-title":"A\u00a0benefit-risk assessment of sibutramine in the management of obesity","volume":"26","author":"Nisoli","year":"2003","journal-title":"Drug Saf"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914912026410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914912026410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:03:09Z","timestamp":1762077789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914912026410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0002914912026410"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2012.12.038","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in Cardiovascular Risk Associated With Phentermine and Topiramate Extended-Release in Participants With Comorbidities and a Body Mass Index \u226527 kg\/m2","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2012.12.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}